99 related articles for article (PubMed ID: 31266008)
1. Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials.
Tiu C; Loh Z; Gan CL; Gan H; John T; Hawkes E
Oncology; 2019; 97(5):270-276. PubMed ID: 31266008
[TBL] [Abstract][Full Text] [Related]
2. Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World.
Karim S; Xu Y; Kong S; Abdel-Rahman O; Quan ML; Cheung WY
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):e160-e166. PubMed ID: 31133363
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
4. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
Al-Baimani K; Jonker H; Zhang T; Goss GD; Laurie SA; Nicholas G; Wheatley-Price P
Curr Oncol; 2018 Aug; 25(4):e291-e297. PubMed ID: 30111974
[TBL] [Abstract][Full Text] [Related]
5. Eligibility of real-world patients with metastatic breast cancer for clinical trials.
Batra A; Kong S; Cheung WY
Breast; 2020 Dec; 54():171-178. PubMed ID: 33120082
[TBL] [Abstract][Full Text] [Related]
6. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
7. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
Statler A; Othus M; Erba HP; Chauncey TR; Radich JP; Coutre S; Advani A; Nand S; Ravandi F; Mukherjee S; Sekeres MA
Blood; 2018 Jun; 131(25):2782-2788. PubMed ID: 29618479
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
[TBL] [Abstract][Full Text] [Related]
9. Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
Tong KM; Laskin J; Ho C
Lung Cancer; 2015 Mar; 87(3):296-302. PubMed ID: 25601487
[TBL] [Abstract][Full Text] [Related]
10. Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials.
Baggstrom MQ; Waqar SN; Sezhiyan AK; Gilstrap E; Gao F; Morgensztern D; Govindan R
J Thorac Oncol; 2011 Jan; 6(1):98-102. PubMed ID: 21150469
[TBL] [Abstract][Full Text] [Related]
11. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Somer RA; Sherman E; Langer CJ
Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
[TBL] [Abstract][Full Text] [Related]
12. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.
Shah JJ; Abonour R; Gasparetto C; Hardin JW; Toomey K; Narang M; Srinivasan S; Kitali A; Zafar F; Flick ED; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):575-583.e2. PubMed ID: 28886839
[TBL] [Abstract][Full Text] [Related]
14. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.
Shao YY; Wu CH; Lu LC; Chan SY; Ma YY; Yen FC; Hsu CH; Cheng AL
J Hepatol; 2014 Feb; 60(2):313-8. PubMed ID: 24036008
[TBL] [Abstract][Full Text] [Related]
16. Resected Lung Cancer Patients Who Would and Would Not Have Met Screening Criteria.
Farjah F; Wood DE; Zadworny ME; Rusch VW; Rizk NP
Ann Thorac Surg; 2016 Jan; 101(1):274-9. PubMed ID: 26298169
[TBL] [Abstract][Full Text] [Related]
17. Stage III non-small-cell lung cancer: Establishing a benchmark for the proportion of patients suitable for radical treatment.
Al-Shamsi HO; Al Farsi A; Ellis PM
Clin Lung Cancer; 2014 Jul; 15(4):274-80. PubMed ID: 24685356
[TBL] [Abstract][Full Text] [Related]
18. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
